Modeling human brain rhabdoid tumor by inactivating tumor suppressor genes in induced pluripotent stem cells

Timothy Hua; Yu Xue; Drishty B Sarker; Sonia Kiran; Yan Li; Qing-Xiang Amy Sang

doi:10.1016/j.bioactmat.2023.08.009

Modeling human brain rhabdoid tumor by inactivating tumor suppressor genes in induced pluripotent stem cells

Bioact Mater. 2023 Aug 12:31:136-150. doi: 10.1016/j.bioactmat.2023.08.009. eCollection 2024 Jan.

Authors

Timothy Hua¹, Yu Xue¹, Drishty B Sarker¹, Sonia Kiran¹, Yan Li^{2

3}, Qing-Xiang Amy Sang^{1

3}

Affiliations

¹ Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL, 32306-4390, USA.
² Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL, 32310-6046, USA.
³ Institute of Molecular Biophysics, Florida State University, Tallahassee, FL, 32306-4380, USA.

Abstract

Atypical teratoid/rhabdoid tumor (ATRT) is a rare childhood malignancy that originates in the central nervous system. Over ninety-five percent of ATRT patients have biallelic inactivation of the tumor suppressor gene SMARCB1. ATRT has no standard treatment, and a major limiting factor in therapeutic development is the lack of reliable ATRT models. We employed CRISPR/Cas9 gene-editing technology to knock out SMARCB1 and TP53 genes in human episomal induced pluripotent stem cells (Epi-iPSCs), followed by brief neural induction, to generate an ATRT-like model. The dual knockout Epi-iPSCs retained their stemness with the capacity to differentiate into three germ layers. High expression of OCT4 and NANOG in neurally induced knockout spheroids was comparable to that in two ATRT cell lines. Beta-catenin protein expression was higher in SMARCB1-deficient cells and spheroids than in normal Epi-iPSC-derived spheroids. Nucleophosmin, Osteopontin, and Ki-67 proteins were also expressed by the SMARCB1-deficient spheroids. In summary, the tumor model resembled embryonal features of ATRT and expressed ATRT biomarkers at mRNA and protein levels. Ribociclib, PTC-209, and the combination of clofilium tosylate and pazopanib decreased the viability of the ATRT-like cells. This disease modeling scheme may enable the establishment of individualized tumor models with patient-specific mutations and facilitate high-throughput drug testing.

Keywords: Atypical teratoid/rhabdoid tumor; Brain tumor modeling; CRISPR/Cas9 gene editing; Human induced pluripotent stem cells; SMARCB1; Tumor suppressor genes.